Published online Feb 25, 2017. doi: 10.5495/wjcid.v7.i1.1
Peer-review started: August 27, 2016
First decision: October 28, 2016
Revised: November 18, 2016
Accepted: December 1, 2016
Article in press: December 2, 2016
Published online: February 25, 2017
Processing time: 181 Days and 11.7 Hours
Hepatitis C virus (HCV) infection represents one of the major causes of chronic liver disease, hepatocellular carcinoma and morbidity/mortality worldwide. It is also a major burden to the healthcare systems. A complete elimination of the HCV from the body through treatment is now possible. However, HCV not only alters the hepatic function. Several extra-hepatic manifestations are present in HCV-infected patients, which increase the mortality rate. Liver and gut are closely associated in what is called the “gut-liver axis”. A disrupted gut barrier leads to an increase in bacterial translocation and an activation of the mucosal immune system and secretion of inflammatory mediators that plays a key role in the progression of liver disease towards decompensated cirrhosis in HCV-infected patients. In addition, both qualitative and quantitative changes in the composition of the gut microbiota (GM) and states of chronic inflammation have been observed in patients with cirrhosis. Thus, a successful treatment of HCV infection should be also accompanied by a complete restoration of GM composition in order to avoid activation of the mucosal immune system, persistent inflammation and the development of long-term complications. Evaluation of GM composition after treatment could be of interest as a reliable indicator of the total or partial cure of these patients. However, studies focused on microbiota composition after HCV eradication from the body are lacking, which opens unique opportunities to deeply explore and investigate this exciting field.
Core tip: Hepatitis C infection represents one of the major causes of chronic liver disease, hepatocellular carcinoma and morbidity/mortality worldwide. A complete elimination of the hepatitis C virus (HCV) from the body through treatment is now possible. However, HCV not only alters the hepatic function. In fact, changes in gut microbiota composition (GM) and gut barrier that leads to an increased bacterial translocation and inflammation have also been observed. Thus, a successful treatment of HCV infection should be accompanied by a complete restoration of GM and inflammation. Studies focused on GM after HCV eradication are lacking, which opens unique opportunities to deeply explore this exciting field.